Küçük Hücreli Dışı Akciğer Kanserinde Adjuvan Tedavi

Akciğer kanseri, dünya çapında en yaygın kanser olup, 2012 yılında yaklaşık 1,8 milyon yeni olgunun geliştiği ve 1,6 milyon ölüme neden olduğu tahmin edilmektedir. Küçük hücreli dışı akciğer kanseri (KHDAK), tüm akciğer kanserlerinin yaklaşık %85’ini oluşturur. Erken evre KHDAK’li hastalar küratif amaçla cerrahi ile tedavi edilir. Ancak, birçok hasta tam rezeksiyona rağmen nüks riski ile karşı karşıyadır. Bu durum hastaların büyük bir kısmının rezeksiyon sırasında mikrometastatik hastalığa sahip olduğunu düşündürmektedir. Bu derlemede KHDAK‘de sağkalımı iyileştirmek için yapılan adjuvan kemoterapi, hedefe yönelik tedavi ve immünoterapi çalışmalarının sonuçlarının değerlendirilmesi amaçlanmıştır.

Adjuvant Treatment in Non-Small Cell Lung Cancer

Lung cancer occurred in approximately 1,8 million patients and caused an estimated 1,6 million deaths in 2012, worldwide. NSCLC constitutes approximately 85% of all lung cancers. Patients with early-stage NSCLC are surgically treated for curative goals. However, many patients are at risk of recurrence despite complete resection. This suggests that a large proportion of patients have the micrometastatic disease even at the early course of the disease. In this review, we aimed to evaluate the results of adjuvant chemotherapy, targeted therapy and immunotherapy studies to improve survival in NSCLC.

PDF

___

Brambilla E, Travis WD. Lung cancer. In: World Cancer Report, Stewart BW, Wild CP, editors. Lyon: World Health Organization;2014.
Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1 Suppl):21S.
Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg. 2006;80:2051–2056.
Fry WA, Phillips JL, Menck H, et al. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867–1876.
Strauss G. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin N Am. 2005;19:263–281.
Non-Small-Cell Lung Cancer Colloaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.
Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2009;28:29–34.
Strauss GM, Herndon JE, Maddus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Study Groups. J Clin Oncol. 2008;26:5043–5051.
Douillard JY, Rosell R, de Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7:719–727.
Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatinbased chemotherapy in resected lung cancer. J Clin Oncol. 2009;28:35–42.
Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small-cell lung cancer. J Natl Cancer. Inst. 2003;95:1453–1461.
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–3559.
Kreuter M, Vansteenkiste J, Fischer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013;24:986–992.
Wakelee HA, Dahlberg SE, Keller SM, et al. E1505: adjuvant chemotherapy +/- bevacizumab for early stage NSCLC-Outcomes based on chemotherapy subsets. J Clin Oncol.2016;34S:8507.
NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 4.2018- April 26,2018.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in nonsmall cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105:595–605.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in nonsmall cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105:595–605.
Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33:4007–4014.
Janjigian YY, Park BJ, Zakowski MF, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011;6:569– 575.
Wu YL, Zhong W, Wang Q, et al. Gefitinib (G) versus vinorelbine + cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) nonsmall- cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): a randomized, Phase III trial (CTONG1104). J Clin Oncol. 2017;35S:8500.
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–135.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627– 1639.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387:1540– 1550.
Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497– 1508.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
Lavin Y, Kobayashi S, Leader A, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell 2017;169:750-65. e17.
Kimura H, Matsui Y, Ishikawa A, et al. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother. 2015;64:51-9.
Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGEA3-positive non-small-cell lung cancer (MAGRIT): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:822-835.
Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012;379:823- 832.